Joshua Miller

Risk outcome assessment with novel long-T ITC complex and high sensitivity troponin I and T in patients with suspected acute coronary syndromes: MERITnI substudy

F S Apple, Kevin Buda, Barret P. Wagner, Yader Sandoval et autres

OBJECTIVES: Understanding whether the novel long-T ITC complex might assist in interpreting clinical prognostic utility compared to established cardiac biomarkers is needed. We determined long term major adverse cardiac events (MACE) and all-cause mortality (ACM) predicated on novel long-T ITC complex and …

us (code pays fourni par la source)

Differentiation of regulatory myeloid and T-cells from adult human hematopoietic stem cells after allogeneic stimulation

James M. Mathew, Jes M. Sanders, Robert Cirocco, Joshua Miller et autres

Introduction Donor hematopoietic stem cell (DHSC) infusions are increasingly being studied in transplant patients for tolerance induction. Methods To analyze the fate of infused DHSCs in patients, we developed anin vitroculture system utilizing CD34+DHSCs stimulated with irradiated allogeneic cells in cytokine supplemented …

us (code pays fourni par la source)

Transcriptomic studies in tolerance: Lessons learned and the path forward

Sunil M. Kurian, Thomas Whisenant, James M. Mathew, Joshua Miller et autres

us, ph (code pays fourni par la source)

Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells

Joseph R. Leventhal, Joshua Miller, James M. Mathew, Sunil M. Kurian et autres

us, ph (code pays fourni par la source)

Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses

Josh Levitsky, Joshua Miller, Xuemei Huang, Lorenzo Gallon et autres

Everolimus (EVL) is a novel mTOR-inhibitor similar to sirolimus (SRL) that is used in organ transplant recipients, often in combination with tacrolimus (TAC) or mycophenolate (MPA). The current study aims to determine its effects on regulatory T cells. Increasing concentrations of EVL, …

us (code pays fourni par la source)

Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin

Annapoorani Veerappan, Lisa B. VanWagner, James M. Mathew, Xuemei Huang et autres

ca, us (code pays fourni par la source)

Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells

Lorenzo Gallon, Opas Traitanon, Yuming Yu, Bo Shi et autres

BACKGROUND: Previously, we had reported the role of tacrolimus (TAC) versus sirolimus (SRL) on the generation of regulatory T cells (Tregs) in primary MLR assays with SRL, demonstrating a uniquely supportive effect. However, the mechanisms associated with their actions on alloreactive human …

us (code pays fourni par la source)

Role of Innate and Acquired Immune Mechanisms in Clinical Intestinal Transplant Rejection

James M. Mathew, Panagiotis Tryphonopoulos, Werviston DeFaria, Phillip Ruiz et autres

BACKGROUND: Long-term outcomes of intestinal transplantation are limited by infection and rejection. To understand the underlying immune mechanisms, graft infiltrating and peripheral blood cells were analyzed using multiple ex vivo assays in intestinal transplantation recipients. METHODS: Infiltrating cells from rejected (graft enterectomy …

us (code pays fourni par la source)

Immune Reconstitution in Recipients of Living Donor Kidney/Hematopoietic Stem + Facilitating Cell Transplants

Joseph R. Leventhal, Mary Jane Elliott, Esma S. Yolcu, Larry D. Bozulic et autres

Abstract Solid organ transplant recipients generally require life-long immunosuppressive agents to maintain graft acceptance. This is associated with a number of toxicities, including renal dysfunction, metabolic abnormalities, opportunistic infection and malignancies. Calcineurin inhibitors, the most frequently used agents for immunosuppression, induce nephrotoxicity, …

us (code pays fourni par la source)

OR26

James M. Mathew, Xuemei Huang, Joseph R. Leventhal, Lorenzo Gallon et autres

us (code pays fourni par la source)

Update On Phase 2 Clinical Trial To Induce Tolerance In Mismatched Living Donor Renal Transplant Recipients

Joseph R. Leventhal, Michaël Abécassis, Joshua Miller, Lorenzo Gallon et autres

Nineteen subjects have been enrolled in a phase 2 protocol (FDA IDE 13947) to induce donor-specific tolerance in HLA-mismatched related and unrelated recipients of living donor renal allografts (KTx). The protocol is based upon tolerogenic CD8+/TCR- facilitating cells (FC) and nonmyeloablative conditioning. …

us (code pays fourni par la source)

Chimerism and Tolerance Without Gvhd In Mismatched Recipients Of Combined Hematopoietic Stem Cell/Kidney Transplants: Donor-Specific Hyporeactivity Is Not a Reliable Biomarker For Tolerance

Joseph R. Leventhal, Michaël Abécassis, Joshua Miller, Lorenzo Gallon et autres

Abstract We recently reported that low-intensity conditioning combined with facilitating cell (FC)-enriched hematopoietic stem cell transplantation (FCRx) can safely achieve high levels of durable chimerism in unrelated and related mismatched kidney transplant (KTx) recipients. This is associated with stable renal function, complete …

us (code pays fourni par la source)